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Dysfunctional high-density 
lipoprotein activates toll-like 
receptors via serum amyloid A in 
vascular smooth muscle cells
Mirjam schuchardt1, Nicole prüfer1, Yuexing tu1,2, Jaqueline Herrmann1, Xiu-ping Hu1, 
sarah Chebli1, Katja Dahlke3, Walter Zidek1, Markus van der Giet1 & Markus tölle1
Serum amyloid A (SAA) is an uremic toxin and acute phase protein. It accumulates under inflammatory 
conditions associated with high cardiovascular morbidity and mortality in patients with sepsis or 
end-stage renal disease (esRD). sAA is an apolipoprotein of the high-density lipoprotein (HDL). sAA 
accumulation turns HDL from an anti-inflammatory to a pro-inflammatory particle. SAA activates 
monocyte chemoattractant protein-1 (MCP-1) in vascular smooth muscle cells. However, the SAA 
receptor-mediated signaling pathway in vascular cells is poorly understood. therefore, the sAA-
mediated signaling pathway for MCP-1 production was investigated in this study. The SAA-induced 
MCP-1 production is dependent on the activation of TLR2 and TLR4 as determined by studies with 
specific receptor antagonists and agonists or siRNA approach. Experiments were confirmed in tissues 
from TLR2 knockout, TLR4 deficient and TLR2 knock-out/TLR4 deficient mice. The intracellular signaling 
pathway is IκBα and subsequently NFκB dependent. The MCP-1 production induced by SAA-enriched 
HDL and HDL isolated from septic patients with high SAA content is also TLR2 and TLR4 dependent. 
Taken together, the TLR2 and TLR4 receptors are functional SAA receptors mediating MCP-1 release. 
Furthermore, the TLR2 and TLR4 are receptors for dysfunctional HDL. These results give a further inside 
in SAA as uremic toxin involved in uremia-related pro-inflammatory response in the vascular wall.
Serum amyloid A (SAA) is a highly conserved acute-phase protein predominantly synthesized by the liver1. The 
precise physiological and pathophysiological role of SAA in acute and chronic inflammatory disorders is not 
known so far. It is well known that SAA plasma levels are elevated during septic conditions2. Other findings 
support the role of SAA in cardiovascular diseases and atherosclerosis3–5. SAA is involved in immune defense 
mechanisms via acting chemotactic to different cell types and binding to gram-negative bacteria1. Furthermore, 
SAA plasma levels are significantly increased in patients with chronic kidney disease (CKD) and end-stage renal 
disease (ESRD)6–8 where an independent correlation with the cardiovascular risk exists8. Cardiovascular dis-
ease is the leading cause of death in patients with CKD. The mortality rate is up to 30-fold increased in patients 
with ESRD compared to renal-healthy patients9,10. Once released into the blood circulation, the apolipoprotein 
SAA mainly incorporates into high-density lipoprotein (HDL), mainly HDL3, but it can also be identified in 
low amounts in low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL)1,11. As a consequence, 
SAA-loaded HDL changes its composition during uremic condition resulting in a less anti-inflammatory capac-
ity12. SAA incorporation is associated with disturbed metabolism13,14 and decreased anti-inflammatory capacity 
of HDL especially from uremic patients6,7.
During inflammation, SAA expression and secretion is induced by several mediators in different cells, like 
macrophages, endothelial cells, and vascular smooth muscle cells (VSMC)1. Four different isoforms of SAA are 
found in the genome: SAA1, SAA2, SAA3, and SAA41. In humans, SAA3 is a pseudo gene1. While SAA4 is 
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constitutively produced, SAA1 and SAA2 serum concentration increases up to 1000-fold under acute inflamma-
tory conditions with an approximate half-life of 24 h1.
As in vitro studies using recombinant human SAA (rhSAA) suggest, several structural diverse cell surface 
receptors are activated by SAA1. Up to now, at least 7 receptors have been identified: formyl-peptide receptor-like 
1 (FPR2)6,15,16, toll-like receptor 2 and 4 (TLR2, TLR4)17–20, scavenger receptor type B-I (SR-BI)21, CD3622,23, 
receptor for advanced glycation end-products (RAGE)20,24,25, and the purinoceptor P2X726.
The aim of this study was to examine the role of these receptors, especially TLR2 and TLR4, for chemokine 
activation in VSMC and macrophages. Our results indicate that beside FPR2 activation6 the TLR2 and TLR4 
regulate the stimulation of MCP-1 production.
Results
HDL-bound-SAA induces MCP-1 production. From previous studies it was known that SAA enrich-
ment of HDL in CKD patients turns this lipid particle to a pro-inflammatory state6,7. Stimulation of rVSMC with 
HDL from septic patients containing a high SAA concentration significantly induced MCP-1 mRNA expression 
compared to HDL from healthy subjects (Fig. 1). When HDL from healthy subjects was spiked with recombinant 
SAA in different dose, this artificial HDL-SAA also stimulated MCP-1 mRNA expression (Fig. 1).
The signaling pathway that is responsible for the SAA-induced pro-inflammatory reaction in VSMC is not 
entirely clear up to now. As known from a previous study, FPR2 is involved in SAA-mediated MCP-1 production 
in rVSMC6. However, the influence of other receptors activated by SAA remains open. Therefore, these receptors 
were investigated in the next step of this study.
Receptor expression. All of the known receptors (FPR2, TLR2, TLR4, SR-BI, CD36, RAGE, P2X7) poten-
tially activated by SAA are expressed in rVSMC (Suppl. Fig. 1). First, the impact of SAA stimulation on receptor 
expression in rVSMC was investigated. After stimulation for 4 h, 24 h or 48 h, the mRNA expression levels of 
P2X7, TLR2, and TLR4 significantly increased compared to control (Fig. 2). The expression increase in TLR2 was 
the most abundant one and reached up to 67-fold after 24 h of stimulation. In contrast, the mRNA expression 
of CD36, SR-BI, or RAGE were not affected (Suppl. Fig. 2A–C). The expression of FPR2 was shown previously6.
Influence of P2X7, TLR2 and TLR4 on SAA-mediated MCP-1 production in rVSMC. Given the 
involvement of P2X7, TLR2, and TLR4 in inflammatory conditions27,28 as well as its regulated expression upon 
SAA stimulation, we further characterized their role in MCP-1-mediated signaling.
To investigate viability effects of agonists and antagonists on cells, a cell viability assay based on metabolism 
was performed and showed no significant changes in the tested cells (Suppl. Fig. 3). The TLR2 agonist HKSA and 
the TLR4 agonist LPS significantly increased the MCP-1 mRNA expression and protein secretion in rVSMC, 
whereas the P2X7 agonist BzATP showed no significant effect (Fig. 3A,B). In line, the P2X7 antagonist KN-62 did 
not influence SAA-induced MCP-1 mRNA expression and protein secretion, whereas co-stimulation of rVSMC 
with the TLR4 antagonist CLI-095 and with the combined TLR2/4 antagonist OxPAPC significantly diminished 
MCP-1 mRNA expression and protein secretion (Fig. 3C,D). In line, antagonists for SR-BI (FPS-ZM1) or RAGE 
(BLT-1) had no influence on SAA-induced MCP-1 mRNA expression (Suppl. Fig. 2D,E). To confirm the effects 
of SAA on TLR2 and TLR4, a second cell line was used. In the macrophage like cell THP-1, the impact of TLR2 
and TLR4 for MCP1 production could be verified. A significant MCP-1 protein secretion is induced by the TLR4 
agonist LPS, but not by the TLR2 agonist HKSA. OxPAPC, CU-CPT22 and CLI-095 significantly diminished the 
SAA- and LPS-induced MCP-1 protein secretion in THP-1 cells (Fig. 3E,F).
MCP-1 production in TLR2 and TLR4 knock-down cells and knock-out mice. In order to confirm 
the role of TLR2 and TLR4 in SAA-mediated MCP-1 signaling in VSMCs, both receptors were silenced by siRNA 
approach. SAA-induced MCP-1 mRNA expression was inhibited in TLR2 and TLR4 single-knock-down cells 
(TLR2siRNA, TLR4siRNA) and double-knock-down cells (TLR2/4siRNA) after 24 hours of stimulation (Fig. 4A). LPS 
as TLR4 agonist induced MCP-1 mRNA expression in TLR2siRNA, but the effect was significantly diminished 
in TLR4siRNA and TLR2/4siRNA (Fig. 4B). In line, the TLR2 agonist HKSA induced MCP-1 mRNA expression in 
TLR4siRNA but the effect was significantly reduced in TLR2siRNA and TLR2/4siRNA (Fig. 4C). These findings were 
confirmed in TLR2 knock-out (TLR2ko), TLR4 deficient (TLR4def) and combined TLR2ko/TLR4def mice. While 
SAA stimulation of aortic rings ex vivo induced a significant MCP-1 protein secretion in wild type mice, the effect 
Figure 1. HDL from septic patients and SAA-spiked HDL from healthy controls induce MCP-1 mRNA 
expression. MCP-1 mRNA expression in rVSMC upon HDL (100 µg/ml) stimulation for 4 h. Data are presented 
as means ± SEM. *p < 0.05 compared to control (ctrl.).
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was significantly diminished in TLR2ko and TLR4def tissue and blocked in TLR2ko/TLR4def aortic tissue (Fig. 4D). 
The TLR mRNA expression in the mice was proven via PCR (Suppl. Fig. 4).
NFκB signaling and TLR mediated MCP-1 production. Since NFκB is the intracellular signaling 
pathway after TLR2 and TLR4 activation, this effect was investigated in the next step. SAA time-dependently 
stimulated phosphorylation of IκBα with subsequent degradation and translocation of NFkB into the nucleus 
(Fig. 5A). TLR inhibition with OxPAPC significantly diminished IκBα phosphorylation (Fig. 5B). To confirm 
that the SAA-mediated MCP-1 production is TLR dependent in rVSMC, cells were pre-incubated with the NFκB 
inhibitor Bay11–7082 upon stimulation with SAA. MCP-1 mRNA expression and protein secretion was signifi-
cantly reduced by Bay11-7082 (Fig. 5C,D). These data demonstrate the NFkB-mediated TLR2 and TLR4 activa-
tion upon SAA stimulation of the cells.
HDL-bound SAA induce MCP-1 production in a TLR2- and TLR4-dependent manner. Since HDL 
and SAA-spiked HDL induced MCP-1 production in VSMCs, next, the TLR2 and TLR4-dependency was investi-
gated. As shown in Fig. 6, OxPAPC significantly diminished the MCP-1 mRNA expression for SAA-spiked HDL, 
whereas no significant influence of the inhibitor was found for HDL from healthy subjects. These data underline 
the TLR2 and TLR4-mediated signaling pathway for SAA in VSMC. To confer these results for HDL bound SAA, 
aortic tissue from TLR2ko, TLR4def and TLR2ko/TLR4def mice were incubated with HDLseptic containing a high SAA 
amount. In accordance to the previous results, ex vivo stimulation of aortic rings induced a significant MCP-1 
Figure 2. SAA-induced receptor expression. Time-dependent (A) P2X7, (B) TLR2 and (C) TLR4 receptor 
mRNA expression in rVSMC upon rhSAA (1 µg/ml) for 4, 24 and 48 h. Data are presented as means ± SEM. 
*p < 0.05 compared to control (ctrl.).
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protein secretion in wild type mice with a significant diminished one in TLR2ko, TLR4def tissue and TLR2ko/
TLR4def mice (Fig. 6B).
Discussion
The present study was designed to investigate the signaling pathway of SAA in vascular cells. The results of this 
study demonstrate that unbound rhSAA and HDL-bound SAA activates pro-inflammatory acting TLR2 and 
TLR4 receptors in vascular cells and therefore, SAA exerts direct action on inflammatory conditions.
Several evidence exists for different SAA functions in the acute and chronic inflammatory disorders; how-
ever, its precise physiological and pathophysiological role and the associated signaling pathways are not entirely 
understood. As in vitro studies revealed, SAA activates several structurally diverse cell surface receptors namely: 
FPR26,15,16, TLR2 and TLR417–20, SR-BI21 and CD3622,23, RAGE20,24,25, and P2X726. As shown here, all of them are 
expressed in the rVSMC serving as experimental model in the present study. In a previous study, we have shown 
the influence of FPR2 for a part of the SAA-induced MCP-1 expression and secretion in rVSMC in a compara-
ble experimental setting6. These data are in line with others who found a FPR2-mediated cytokine production 
upon receptor activation by SAA in vascular cells. Human monocytes and endothelial cells release MCP-1 upon 
SAA-mediated FPR2 activation leading to subsequent phagocyte migration15,29,30. In addition, the chemotaxis 
of monocytes and mast cells is regulated via FPR2 signaling pathway upon SAA31,32. IL-10 and TNFα secretion 
from monocytes33 as well as TNFα and IL-8 secretion from neutrophils16 were reported for SAA-mediated FPR2 
activation. The current study investigates the meaning of further receptors activated by SAA for the remaining 
Figure 3. MCP-1 mRNA expression and protein secretion in rVSMC and THP-1 macrophage-like cell upon 
receptor agonists and antagonists. (A,C) MCP-1 mRNA expression and (B,D–F) MCP-1 protein secretion in 
(A–D) rVMSC or (E,F) THP-1 macrophage-like cells. RhSAA (1 µg/ml), BzATP (100 µmol/l), HKSA (107 cells/
ml), LPS (1 µg/ml), KN-62 (10 µmol/l), OxPAPC (30 µg/ml), CU-CPT22 (10 µmol/l), CLI-095 (10 µmol/l). Data 
are presented as means ± SEM. (A,B,E,F) *p < 0.05 compared to control (ctrl.) or (C,D) compared to SAA-
stimulation.
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part of the MCP-1 production in rVSMC. Here, data from agonist/antagonist studies, siRNA approach and exper-
iments on aortic tissue from receptor knock-out and deficient mice revealed the influence of TLR2 and TLR4 
activation. These data are in line with the literature. SAA-induced cytokine production via activation of TLR2 
has been shown in mouse17,19,26 and human macrophages26,34,35. In a mouse lung model, SAA induced a robust 
TLR2-mediated neutrophilic inflammation36. Comparable results were found in literature for SAA-mediated 
TLR4 activation in inflammatory pathways. SAA-mediated TLR4 activation leads to a subsequent activation of 
the inflammasome in human macrophages26,35 and induces nitric oxide production in murine peritoneal mac-
rophages18. In addition, HMGB1 is released via SAA-mediated TLR4 receptor activation and SAA-neutralizing 
antibodies are protective against endotoxemia in septic patients20.
An influence of the scavenger receptors SR-BI and CD36 could not be found for SAA-induced chemokine 
production in the investigated experimental setting; however, it could also not be excluded. Unfortunately, for 
CD36 no selective agonist and antagonist exist so that the current study only investigated the influence of SAA 
on CD36 mRNA expression, where no effect was found. Baranova and colleagues demonstrated that SAA binds 
and activates CD36 in a setting with CD36 deficient mouse macrophages22. HEK293 cells secreted IL-6 and IL-8 
upon SAA via CD36 activation22. For SR-BI it has been shown that both lipid-free and HDL-bound SAA are able 
to bind and activate SR-BI21. Subsequently, the receptor is internalized by hepatocytes leading to an inhibition 
of HDL uptake21. Although SR-BI is expressed in rVSMC, the data revealed no influence of this receptor in 
SAA-mediated MCP-1 production. Neither the mRNA expression of SR-BI is time-dependently influenced by 
SAA stimulation of rVSMC nor the selective SR-BI inhibitor FPS-ZM1 was able to reduce SAA-induced MCP-1 
production. Similar results were found for RAGE activation. Neither a time-dependent regulation of RAGE 
mRNA expression upon SAA nor an effect of the RAGE antagonist BLT-1 was found in rVSMC regarding MCP-1 
production in the current experimental model. In contrast, SAA induced inflammatory cytokine production as 
IL-6 and IL-8 expression via RAGE activation in synovial fibroblasts24. Furthermore, RAGE activation via SAA 
is involved in the formation of atherosclerotic lesions within the vascular wall25. RAGE knock-out animals were 
protected against uremia-induced acceleration of SAA increase and atherogenesis25. As mentioned already for 
TLR4, the SAA-induced HMGB1 release depends not only on TLR4, but also in RAGE activation20. Therefore, a 
different regulation of SAA induced cytokine production in different vascular cells exists.
Figure 4. Effect of TLR2 and TLR4 verified by siRNA and receptor knockout model. (A–C) rVSMC were 
transfected with siRNA for TLR2 (TLR2siRNA), TLR4 (TLR4siRNA) or both (TLR2/4siRNA) as well as negative 
control siRNA (NC). Mock transfected cells were used as control in all experiments. Afterwards, cells 
were stimulated for 24 h with rhSAA (1 µg/ml), LPS (1 µg/ml) and HKSA (107 cells/ml) with subsequent 
determination of MCP-1 mRNA expression. Data are presented as means ± SEM. *p < 0.05 compared to 
respective control. (D) Aortic tissue of TLR2 knockout (TLR2ko), TLR4 deficient (TLR4def) and TLR2ko/TLR4def 
mice in comparison to control wild type littermates (wt) were stimulated ex vivo with rhSAA (1 µg/ml) for 
24 h, respectively. MCP-1 protein secretion was determined in the supernatant and normalized to the aortic 
dry weight. Data are presented as means ± SEM. *p < 0.05 compared to unstimulated control (ctrl.), #p < 0.05 
compared to wildtype littermate.
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Figure 5. Signalling pathway. (A,B) Ratio of p-IκBα to total IκBα upon rhSAA (1 µg/ml) stimulation for (A) 
5, 10, 30 min and (B) 30 min in combination with OxPAPC (30 µg/ml). (C,D) MCP-1 mRNA expression and 
protein secretion upon rhSAA (1 µg/ml) in co-stimulation with NFκB inhibitor Bay11-7082 (5 µmol/l). (C) 
MCP-1 mRNA expression upon 4 h of stimulation. (D) MCP-1 protein secretion upon 24 h of stimulation. Data 
are presented as means ± SEM. *p < 0.05.
Figure 6. SAA-enriched HDL induced MCP-1 mRNA expression is TLR2 and TLR4 dependent. (A) MCP-1 
mRNA expression in rVSMC upon HDL (100 µg/ml) and OxPAPC (30 µg/ml) stimulation for 4 h. (B) Aortic 
tissue of TLR2ko, TLR4def and TLR2ko/TLR4def mice in comparison to control wild type littermates (wt) were 
stimulated ex vivo with HDL (100 µg/ml) isolated from septic patients (HDLseptic) for 24 h. MCP-1 protein 
secretion was determined in the supernatant and normalized to the aortic dry weight. Data are presented as 
means ± SEM. *p < 0.05 compared to control (ctrl.).
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Regarding P2X7 activation via SAA, it is already known that activation of this purinoceptor leads to activation 
of the inflammasome in human and mouse macrophages26. In the current study however, only an influence of 
SAA on P2X7 expression could be found. Neither a specific P2X7 antagonist nor a specific agonist could verify any 
role of this receptor subtype for MCP-1 production in rVSMC in the current model.
SAA is known for a long time37,38 and its predictive function as biomarker has been shown recently for cardi-
ovascular events in patients with diabetes mellitus type 239 and patients with rheumatoid arthritis40. Infusion in 
mice in an experimental model of atherosclerosis leads to an increase in macrophage-specific reverse cholesterol 
transport and subsequent reduction of the atherosclerotic burden41.
As apolipoprotein, SAA accumulated mainly in HDL42. However, during acute-phase response, the level of 
lipid-free SAA increases in serum and beside hepatic tissue, SAA is also synthesized in peripheral tissues by 
several cell types1. As known from previous studies, high concentration of HDL-bound SAA modifies the func-
tionality of HDL from anti-inflammatory to pro-inflammatory properties6,7. The current study shows that effects 
of HDL from septic patients with high SAA plasma concentrations could be replicated by modifying HDL from 
healthy donors with rhSAA. The pro-inflammatory effect of this modified HDL could be diminished by the 
inhibition of the TLR2 and TLR4 receptor. Therefore, the data of this study revealed pro-inflammatory actions of 
lipoprotein-bound SAA and lipid-free SAA by activation of the TLR2 and TLR4 receptor.
However, others found a diminished chemoattractant property of SAA to human macrophages when it is 
bound to HDL43. Moreover, the TNFα production upon SAA was found to be inhibited by HDL in THP-1 cells44. 
As opposed to those findings, HDL was not able to inhibit binding of SAA to the surface of gram-negative bac-
teria45, where SAA aggregates forms channel forming hexamers46,47. As shown by Malle et al. few years ago48,49, 
the conformation and oligomeric state of SAA seems identical and the same epitopes are exposed in both forms 
in case of lipid-free and HDL-bound form48,49. Why do we observe these divergent results? On the one hand 
HDL-bound SAA has diminished actions whereas on the other hand full action of HDL-bound SAA could be 
observed. This cannot be explained easily, but one has to keep in mind that HDL as lipid particle is full of other 
functional substances that might interfere with SAA actions. This might explain the observed effects. HDL is 
also known to act as a detoxifying agent. It is speculative but not impossible that HDL absorbs SAA to diminish 
negative actions of free SAA, but under uremic or septic conditions HDL cannot function properly because of 
overwhelming production of SAA50.
Although many pro-inflammatory actions of SAA are well described in different experimental settings, 
some anti-inflammatory actions of SAA has also been found1. The anti-inflammatory cytokine IL-10 is induced 
by SAA17,33,51, the oxidative stress of neutrophils is reduced52, and the inflammatory response in a pneumonia 
mice model was inhibited by SAA53. In addition, the proliferation of regulatory T cells is induced upon SAA54. 
However, the physiological role of these described anti-inflammatory actions of SAA in vivo are not clear and 
could only be speculated.
We cannot fully exclude the influence of other pro-inflammatory acting HDL associated compounds under 
septic conditions, but the high HDL-associated SAA concentration plays a major role in the pro-inflammatory 
property of HDL as shown by the artificially enriched SAA within HDL from healthy controls. This effect is com-
parable with HDL isolations from septic patients.
In summary, our data provide an additional line of evidence that SAA accumulation in HDL reduces its 
anti-inflammatory capacity by activating pro-inflammatory signaling pathways. SAA plays a key role in decreased 
HDL functionality and therefore represents an interesting therapeutic target for influencing the fate of cardio-
vascular disease. However, a direct pharmacological treatment by receptor antagonists might be hampered by 
the variety of receptors activated by SAA. But, there is now very good evidence that targeting of TLR2 and TLR4 
receptors might be of interest.
Methods
Materials. All cell culture media, supplements and PBS Dulbecco’s (w/o Ca2+/Mg2+ pH 7.4) are purchased 
from Biochrom AG, Berlin, if it’s not mentioned otherwise. All cell culture media were supplemented with 1% 
(v/v) penicillin/streptomycin. Dulbecco’s Modified Eagle’s medium (DMEM) and Rosewell Park Memorial 
Institute (RPMI) media were supplemented with 10% (v/v) heat-inactivated fetal bovine serum. The digestion 
solution TrypLE™ Express and RPMI media were purchased from Gibco® by Live Technologies, Karlsruhe.
Substances: recombinant human SAA (rhSAA, contains SAA1 and SAA2, Peprotech, Hamburg, Germany), 
LPS (Sigma-Aldrich, Munich, Germany), HKSA (InvivoGen, Toulouse, France), Bz-ATP (Sigma-Aldrich, 
Munich, Germany), OxPAPC (InvivoGen, Toulouse, France), KN-62 (Sigma-Aldrich, Munich, Germany), CLI-
095 (TAK-242, InvivoGen, Toulouse, France), Bay11-7082 (Calbiochem, MerckMillipore, Darmstadt, Germany).
Animals. This study was carried out in accordance with the recommendation in the Guide for the Care and 
Use of Laboratory Animals and was approved by the Landesamt fuer Gesundheit und Soziales Berlin, Germany. 
Explantation of aortic tissue was performed under sodium pentobarbital anesthesia (400 mg/kg body weight, 
intraperitoneal). For VSMC isolation, Wistar rats were used. For the ex vivo experiments, the following mouse 
strains were used: C57BL/10ScN, which are naturally deficient for TLR455,56, C57BL/10ScSn-TLR2tm1, which 
have an induced knockout for TLR257,58, C57BL/10ScSn-TLR4/TLR2, where mice with induced TLR2 knockout 
were crossed with naturally TLR4 deficient mice, and C57BL/10ScSn as control mice.
HDL isolation. HDL was isolated of human blood. The blood sampling has been carried out in accordance 
with the Declaration of Helsinki of the World Medical Association, and has been approved by the local Ethics 
Committee of the Charité, Berlin, Germany. All participants signed an informed consent for study participation. 
Blood of healthy control subjects and sepsis patients was used for experiments. HDL was isolated from human 
serum as described previously6. For indicated experiments, HDL of healthy control subjects was spiked with 
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SAA. Therefore, HDL was incubated for 4 h at 37 °C with 25 µg/ml and 100 µg/ml rhSAA. Afterwards, the sam-
ple was centrifuged repeatedly using a cutt-off filter to separate unbound SAA from HDL-bound SAA. For the 
experiments, only the HDL-bound SAA was used. Concentrations of SAA were checked using SAA ELISA (IBL, 
Germany) according to the manufacturer´s instructions.
Isolation of rat vascular smooth muscle (cells from rat aortas). Wistar rats were euthanized by an 
overdose of pentobarbital. The thoracic aorta was cut from the arch to the diaphragm under aseptic conditions, 
cleaned, infused by phosphate-buffered saline (PBS) buffer (37 °C) and the adventitial layer was removed using a 
microscissor. rVSMC were isolated by explant outgrowth method as described previously59.
Cell culture. rVSMC were cultured in DMEM (1.0 g/L glucose) supplemented with 10% fetal bovine serum 
(FBS), penicillin (100 U/mL), streptomycin (100 µg/mL), and stable L-glutamine. Cells were maintained at 37 °C 
in a humidified atmosphere with 5% CO2 in air. THP-1 cells were obtained from the DSMZ Braunschweig, 
Germany (ACC 16). Cells were cultured in RPMI 1640 media containing 10% fetal calf serum, 1% antibiot-
ics. THP-1 monocyte differentiation into macrophages was induced by treatment with phorbol-12-myristate-
13-acetate (PMA) for 24 h60.
RNA isolation and reverse transcription pCR analysis. Total RNA from rVSMC was isolated using 
RNeasy® Mini Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. The purity and amount 
of RNA were determined by measuring the OD at the ratio of 260 to 280 nm via NanoDrop photometer (Thermo 
Fisher Scientific, Dreieich, Germany). RNA was reverse transcribed into cDNA using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems/Life Technologies, Darmstadt, Germany) following the manufac-
turer’s instructions. The purity and amount of cDNA were determined by measuring the OD at the ratio of 260 to 
280 nm via NanoDrop photometer.
Detection of MCP-1 production. For the gene expression studies, rVSMC were serum starved for 24 h 
prior stimulation. Afterwards, cells were stimulated for 4 h with agonists. In case of antagonistic studies, antag-
onists were pre-incubated for 30 min. MCP-1 mRNA expression was determined by quantitative real-time PCR 
using the CFX96/384 System and appropriated SybrGreen kit (Bio-Rad, Muenchen, Germany). The oligonucle-
otides were synthesized by TibMolBiol (Berlin, Germany). The oligonucleotide sequences are specified in the 
Supplementary Table 1. Quantification of gene expression was normalized using β-actin as a house keeping gene.
MCP-1 protein secretion was measured in supernatants of stimulated cells (rVSMC, THP-1) and ex vivo stim-
ulation of aortic rings. Stimulation was performed for 24 h. Cells were serum-starved for 24 h prior stimulation. 
After stimulation, supernatants were collected for quantification of MCP-1 protein secretion. MCP-1 protein 
was measured with the Milliplex® map kit for rat or human MCP-1 protein (Millipore, Schwalbach, Germany) 
according to manufacturer’s instruction using Luminex™ technique (BioRad, Muenchen, Germany). MCP-1 
secreted protein was normalized to the total protein content of the lyzed cells or aortic dry weight.
Cell transfection for TLR2 and TLR4 silencing. Cells were serum starved for 48 h prior gene silencing 
experiments. Rat aortic VSMCs were trypsinized, counted, resuspended in transfection solution and were trans-
fected with pre-designed small interference RNA (siRNA) against TLR2 and TLR4 (Applied Biosystems/Life 
Technologies, Darmstadt, Germany) or non-related scrambled nucleotides with similar GC content (Invitrogen/
Life Technologies, Darmstadt, Germany) by electroporation using the Amaxa Nucleofector II system and Amaxa 
Basic Nucleofector kit solution for primary VSMC (Lonza, Koeln, Germany). The knockdown efficiency of siRNA 
on TLR2 and TLR4 mRNA expression is ~80% (Suppl. Fig. 5).
Detection of signaling molecule IkB-a. Cultured cells were serum starved for 48 h prior to stimulation. 
VSMCs were stimulated for 1 to 30 min with SAA and OxPAPC. The antagonist was pre-incubated for 30 minutes. 
For the quantification of phosphorylated proteins, cells were washed with ice-cold PBS and lyzed using a buffer 
included in the kit (Bio-Plex® Cell Lysis Kit). Total content of IkB-a and phosphorylated IkB-a (p-IkB-a) was 
measured with the Bio-Plex® Phosphoprotein Detection Kit (BioRad, Muenchen, Germany) according to man-
ufacturer´s instruction using Luminex™ technique (BioRad, Muenchen, Germany). The phosphorylated protein 
was normalized to the total protein content of the lyzed cells.
statistical analysis. Data are provided as mean ± SEM. The experiments were repeated at least in 3 inde-
pendent experiments or in the number as indicated. Statistical analysis was performed using GraphPad Prism 
software (version 5.0). To evaluate differences between treatment groups Mann-Whitney U test or Wilcoxon 
matched paired test were applied. A p value < 0.05 was considered as statistically significant.
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